- Home
- HCA vs SNY Comparison
HCA vs SNY Comparison
Compare HCA & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCA | SNY |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5B | 104.5B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | HCA | SNY |
|---|---|---|
| Price | $392.42 | $42.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 5 |
| Target Price | ★ $511.84 | $58.00 |
| AVG Volume (30 Days) | 1.7M | ★ 3.5M |
| Earning Date | 04-24-2026 | 04-23-2026 |
| Dividend Yield | 0.72% | ★ 3.47% |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 7.15 | N/A |
| Revenue | ★ $75,600,000,000.00 | N/A |
| Revenue This Year | $5.11 | $3.49 |
| Revenue Next Year | $4.86 | $6.10 |
| P/E Ratio | $54.16 | ★ $6.14 |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $330.00 | $40.89 |
| 52 Week High | $556.52 | $52.68 |
Technical Indicators
Market Signals| Indicator | HCA | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 46.49 |
| Support Level | $390.10 | $42.30 |
| Resistance Level | $399.38 | $48.76 |
| Average True Range (ATR) | 10.14 | 0.73 |
| MACD | 3.96 | -0.12 |
| Stochastic Oscillator | 83.10 | 47.10 |
Price Performance
Historical ComparisonAbout HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.